Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
NEW YORK, NY, May 02, 2018 -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it will be presenting at the 3rd annual Disruptive Growth & Healthcare Conference on Tuesday, May 8th at 12:50pm EDT. Tom LaVoy, CEO of IsoRay, will be presenting as well as meeting with investors.
Tom LaVoy, IsoRay’s CEO, will also be a participant on a panel discussion at 1:45pm EDT entitled “Disruptive Injectables & Oncology”.
The 2018 Disruptive Growth & Healthcare Conference will offer the exclusive opportunity to discover life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models.
For those interested in attending, please visit www.DisruptNYC.com for more information.
About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay. Follow us on Twitter@IsoRay.
About RHK Capital:
Advisory Group Equity Services, Ltd. (dba RHK Capital) was founded in 1984. RHK Capital is a boutique investment banking firm specializing in small to medium-sized transactions. RHK is led by a management team with extensive financial industry experience and a desire to provide companies and individuals with the tools and expertise to accomplish their financial goals. In addition to investment banking, RHK has grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, investment management, mortgages, and business lending. As a division of Advisory Group Equity Services (AGES), all securities are offered through Advisory Group Equity Services Ltd., a registered broker-dealer, member of the Financial Industry Regulatory Authority and the Securities Investor Protection Corporation.
Contacts: IsoRay Inc. [email protected] (509) 375-1202 Investors: Stephanie Prince, Managing Director PCG Advisory Group [email protected] (646) 762-4518
